Biotechnology
ImmunoPrecise Antibodies’ Subsidiary U-Protein Express Announces Exclusive Agreement as Global Supplier for Wnt-Surrogate-Fc Growth Factor
VICTORIA, April 25, 2019 /CNW/ – ImmunoPrecise Antibodies Ltd.(TSX:IPA)(OTC:IPATF)(FRA: TQB2)(the “Company” or “IPA”) U-Protein Express, a wholly-owned ImmunoPrecise Antibodies subsidiary, in Utrech, Netherlands, announced that it has obtained an exclusive license from Stanford University to ... [Read]
Biotechnology
ImmunoPrecise to Present at the 2019 Bloom Burton and Co. Healthcare Investor Conference
VICTORIA, April 16, 2019 /CNW/ – ImmunoPrecise (TSX:IPA)(OTC:IPATF)(FRA: TQB2)(the “Company” or “IPA”)announced today that Jennifer Bath, President and CEO of ImmunoPrecise Antibodies, will present at the upcoming 2019 Bloom Burton & Co. Healthcare Investor Conference. Date: May 1st, 2019 Time: 2:00 ... [Read]
Biotechnology
ImmunoPrecise Appoints Andy Nixon to Board of Directors
VICTORIA, April 11, 2019 / – ImmunoPrecise (TSX:IPA)(OTC:IPATF)(FRA: TQB2)(the “Company” or “IPA”) announces that it has appointed Andy Nixon, Vice President of Biotherapeutics Molecule Discovery at Boehringer Ingelheim, as a member of its board of directors. ... [Read]
Editorspicks
TetraGenetics and ImmunoPrecise Extend Collaboration by Signing Multi-Target Service Agreement for the Discovery of Therapeutic Antibodies
VICTORIA, April 9, 2019 /CNW/ – ImmunoPrecise (TSX:IPA)(OTC:IPATF)(FRA: TQB2)(the “Company” or “IPA”) is pleased to announce the extension of its collaboration with TetraGenetics, a biopharmaceutical company developing novel therapeutics for autoimmune diseases. The alliance is focused ... [Read]
Editorspicks
ImmunoPrecise Antibodies Leverages Proprietary Technology and Expertise to Create Talem Therapeutics
VICTORIA, April 4, 2019 /CNW/ – ImmunoPrecise (TSX:IPA)(OTC:IPATF)(FRA: TQB2) announces it has formed a wholly-owned, Cambridge, Massachusetts-based subsidiary, Talem Therapeutics (Talem). Talem is focused on the discovery and development of next-generation, fully-human, monoclonal therapeutic antibodies targeting neurology, immuno-oncology, gastroenterology, ... [Read]
Editorspicks
ImmunoPrecise Antibodies Reports Record Q3 2019 Financials Results
VICTORIA, March 27, 2019 /CNW/ – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “ImmunoPrecise”) (TSX:IPA)(OTC:IPATF)(FRA: TQB2) today reports its financial results for Q3 ended January 31, 2019. The financial statements and related management’s discussion and analysis (“MD&A”) can be ... [Read]
Editorspicks
ImmunoPrecise Antibodies Announces DTC Eligibility
VICTORIA, BC, Feb. 28, 2019 /CNW/ – ImmunoPrecise Antibodies Ltd. (TSX:IPA)(OTC:IPATF)(FRA: TQB2) (the “Company” or “IPA”) is pleased to announce that its common shares are now eligible for electronic clearing and settlement through the Depository Trust Company ... [Read]
Editorspicks
ImmunoPrecise Antibodies Announces Resignation of Jos Raats, as Managing Director of ModiQuest Research BV
VICTORIA, BC, March 15, 2019 /CNW/ – ImmunoPrecise Antibodies Ltd. (the “Company” or “IPA”) (TSX:IPA)(OTC:IPATF)(FRA: TQB2) today announces that Jos Raats, Ph.D., has resigned from the position of Managing Director of ModiQuest Research B.V. in order to pursue his ... [Read]
Editorspicks
ImmunoPrecise Antibodies Receives Subcontract to Produce Rabbit Monoclonal Antibodies
VICTORIA, Feb. 21, 2019 /CNW/ – ImmunoPrecise Antibodies Ltd. (TSX:IPA)(OTC:IPATF)(FRA: TQB2) (the “Company” or “IPA”) has received a five-year Indefinite Delivery/Indefinite Quantity (ID/IQ) subcontract from Leidos Biomedical Research, Inc., which currently operates the Frederick National Laboratory for Cancer Research for the National Cancer Institute ... [Read]
Press Release
ImmunoPrecise Hires Jason Orloske as Vice President Operations
Canada NewsWire VICTORIA, Dec. 26, 2018 VICTORIA, Dec. 26, 2018 /CNW/ – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSXV:IPA) (OTC PINK:IPATF) is pleased to announce Jason Orloske has accepted the position of Vice President of Operations for ImmunoPrecise Antibodies Global ... [Read]